Elsevier

Neuroscience Letters

Volume 466, Issue 1, 27 November 2009, Pages 27-29
Neuroscience Letters

Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder

https://doi.org/10.1016/j.neulet.2009.09.019Get rights and content

Abstract

Neuregulin (NRG) 1Iα and NRG3 proteins levels were measured in Brodmann's area 46 from 20 subjects with schizophrenia, 8 subjects with bipolar 1 disorder and 20 age-sex matched control subjects. Protein levels of both NRG1Iα and NRG3 were unchanged in both psychiatric illnesses. These data suggest any change in NRG1Iα and NRG3 expression in schizophrenia or bipolar 1 disorder do not result in changes levels in levels of those proteins Brodmann's area 46.

Section snippets

Acknowledgements

B.D. is a Senior NHMRC Research Fellow (Level B) (400016). S.B. was a recipient of an Ian Scott Scholarship from The Australian Rotary Health Research Fund. The study was funded in part by Rebecca L. Cooper Medical Research Foundation, NHMRC Project Grants # 193299 and the Operational Infrastructure Support (OIS) from the Victorian State Government.

References (26)

  • I. Bertram et al.

    Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression

    Ann. N. Y. Acad. Sci.

    (2007)
  • S. Britsch

    The neuregulin-I/ErbB signaling system in development and disease

    Adv. Anat. Embryol. Cell Biol.

    (2007)
  • Y.J. Chen et al.

    Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components

    J. Neurosci.

    (2008)
  • Cited by (11)

    • Neuregulin-1 and schizophrenia in the genome-wide association study era

      2016, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Despite these limitations, six post-mortem brain, one serum, and one plasma study in humans have been published (Table 7). Two studies have reported on NRG1α, one reporting a decrease in PFC white matter (Bertram et al., 2007) and the other no difference in Brodmann⿿s area 46 (frontal cortex) (Boer et al., 2009). By contrast, NRG1-ICD (intracellular cleavage domain, 53 kDa) levels were found to be increased by 20% in the PFC (Chong et al., 2008) and NRG1-CTF (C-terminal fragment, 55 kDa) levels decreased by 50% in the premotor frontal cortex (Brodmann's area 6) (Barakat et al., 2010) in schizophrenia compared to controls.

    • Dopaminergic function in relation to genes associated with risk for schizophrenia: Translational mutant mouse models

      2014, Progress in Brain Research
      Citation Excerpt :

      Supporting neuropathologic evidence indicating disruption to NRG1/ErbB signaling in schizophrenia derives from studies in human postmortem brain tissue and cell lines (Harrison and Law, 2006; Mei and Xiong, 2008). However, the evidence is equivocal regarding whether up- or downregulation of NRG1/ErbB signaling is implicated in brains from patients with schizophrenia (Chong et al., 2008; Hahn et al., 2006): There have been reports of overexpression of specific NRG1/ErbB4 splice variants (Hashimoto et al., 2004; Law et al., 2006, 2007; Parlapani et al., 2010); another study reported increased expression of the ErbB1 protein (Futamura et al., 2002); other studies have reported either decreased isoform-specific expression of NRG1 transcripts (Parlapani et al., 2010; Shibuya et al., 2010) or no change therein (Boer et al., 2009). The NRG1/ErbB signaling pathway has been shown to influence the expression of key CNS neurotransmitters, including glutamate, GABA, acetylcholine, 5-HT, and DA (Corfas et al., 2004).

    • No genetic evidence for Neuregulin 3 conferring risk of schizophrenia in the Chinese population

      2013, Psychiatry Research
      Citation Excerpt :

      The neuregulin family has four epidermal growth factor-like signalling molecules: NRG1, NRG2, NRG3 and NRG4 (Boer et al., 2009).

    • Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia

      2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry
      Citation Excerpt :

      Interestingly, Hahn et al. (2006) have demonstrated that, although the expression of both NRG1 and ErbB4 receptors did not significantly change in the PFC in schizophrenic subjects compared to normal subjects, the phosphorylation and the activation of downstream signalling of the ErbB4 receptor were elevated. However, another study reported that NRG1α and NRG3 did not change in the PFC of schizophrenic patients in post-mortem study (Boer et al., 2009). In brief, current reports are not completed consistently, however the majority of the data from previous studies have demonstrated either an elevated NRG1 isoform (protein or mRNA) expression or increased ErbB4 receptors (protein or mRNA) expression.

    • Decreased Neuregulin 1 C-terminal fragment in Brodmann's area 6 of patients with schizophrenia

      2010, Schizophrenia Research
      Citation Excerpt :

      Several studies report there is no change in total NRG1 mRNA expression with the illness (Boer et al., 2009; Hashimoto et al., 2004; Law et al., 2004). No difference in NRG1 and NRG3 protein expression was found in prefrontal cortex BA46 (Boer et al., 2009). Hahn et al., 2006 also showed no change in NRG1 or ErbB proteins in the prefrontal cortex of schizophrenic patients, but they reported a decrease in NRG1-ErbB signalling resulting in the impaired function of NMDA receptors.

    View all citing articles on Scopus
    View full text